Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hyperlipoproteinemias

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 53 articles:
HTML format



Single Articles


    March 2021
  1. GIBBONS GH, Seidman CE, Topol EJ
    Conquering Atherosclerotic Cardiovascular Disease - 50 Years of Progress.
    N Engl J Med. 2021;384:785-788.
    PubMed    


    February 2021
  2. RAAL FJ, Gaudet D, Gusarova V
    Evinacumab for Homozygous Familial Hypercholesterolemia. Reply.
    N Engl J Med. 2021;384:e17.
    PubMed    


  3. XU HG
    Evinacumab for Homozygous Familial Hypercholesterolemia.
    N Engl J Med. 2021;384:e17.
    PubMed    


  4. LUO F, Das A, Fang Z
    Evinacumab for Homozygous Familial Hypercholesterolemia.
    N Engl J Med. 2021;384:e17.
    PubMed    


  5. AGIRBASLI M
    Evinacumab for Homozygous Familial Hypercholesterolemia.
    N Engl J Med. 2021;384:e17.
    PubMed    


    January 2021
  6. GAUDET D, Ruzza A, Santos RD
    Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. Reply.
    N Engl J Med. 2021;384:84-85.
    PubMed    


  7. SINGH A, Mittal S, Kazimuddin M
    Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2021;384:84.
    PubMed    


    December 2020
  8. MARTIN SS
    Factoring in ANGPTL3 When LDL Is Refractory.
    N Engl J Med. 2020;383:2385-2386.
    PubMed    


    November 2020
  9. SHAW AT, Bauer TM, de Marinis F, Felip E, et al
    First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
    N Engl J Med. 2020;383:2018-2029.
    PubMed     Abstract available


  10. ROSENSON RS, Burgess LJ, Ebenbichler CF, Baum SJ, et al
    Evinacumab in Patients with Refractory Hypercholesterolemia.
    N Engl J Med. 2020 Nov 15. doi: 10.1056/NEJMoa2031049.
    PubMed     Abstract available


    October 2020
  11. DE FERRANTI SD
    Evolocumab in Children with Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020;383:1385-1386.
    PubMed    


    August 2020
  12. SANTOS RD, Ruzza A, Hovingh GK, Wiegman A, et al
    Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020 Aug 29. doi: 10.1056/NEJMoa2019910.
    PubMed     Abstract available


  13. KERSTEN S
    Bypassing the LDL Receptor in Familial Hypercholesterolemia.
    N Engl J Med. 2020;383:775-776.
    PubMed    


  14. RAAL FJ, Rosenson RS, Reeskamp LF, Hovingh GK, et al
    Evinacumab for Homozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020;383:711-720.
    PubMed     Abstract available


    April 2020
  15. RAY KK, Wright RS, Kallend D, Koenig W, et al
    Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
    N Engl J Med. 2020;382:1507-1519.
    PubMed     Abstract available


    March 2020
  16. RAAL FJ, Kallend D, Ray KK, Turner T, et al
    Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
    N Engl J Med. 2020 Mar 18. doi: 10.1056/NEJMoa1913805.
    PubMed     Abstract available


    January 2020
  17. LUIRINK IK, Kusters DM, Hutten BA
    Statins for Familial Hypercholesterolemia from Childhood. Reply.
    N Engl J Med. 2020;382:488-489.
    PubMed    


  18. MURATA Y, Kami M
    Statins for Familial Hypercholesterolemia from Childhood.
    N Engl J Med. 2020;382:488.
    PubMed    


  19. BIJL D, Hama R
    Statins for Familial Hypercholesterolemia from Childhood.
    N Engl J Med. 2020;382:487-488.
    PubMed    


    December 2019
  20. WITZTUM JL, Geary RS, O'Dea L
    Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia. Reply.
    N Engl J Med. 2019;381:2584.
    PubMed    


  21. KHETARPAL SA, Wang M, Khera AV
    Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia.
    N Engl J Med. 2019;381:2582-2584.
    PubMed    


    October 2019
  22. LUIRINK IK, Wiegman A, Kusters DM, Hof MH, et al
    20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia.
    N Engl J Med. 2019;381:1547-1556.
    PubMed     Abstract available


  23. MICHOS ED, McEvoy JW, Blumenthal RS
    Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease.
    N Engl J Med. 2019;381:1557-1567.
    PubMed    


    September 2019
  24. MUNOZ D, Uzoije P, Reynolds C, Miller R, et al
    Polypill for Cardiovascular Disease Prevention in an Underserved Population.
    N Engl J Med. 2019;381:1114-1123.
    PubMed     Abstract available


    August 2019
  25. WITZTUM JL, Gaudet D, Freedman SD, Alexander VJ, et al
    Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
    N Engl J Med. 2019;381:531-542.
    PubMed     Abstract available


    April 2019
  26. BHATT DL, Steg PG, Miller M
    Cardiovascular Risk Reduction with Icosapent Ethyl. Reply.
    N Engl J Med. 2019;380:1678.
    PubMed    


  27. BORGHI C, Fogacci F, Cicero AFG
    Cardiovascular Risk Reduction with Icosapent Ethyl.
    N Engl J Med. 2019;380:1678.
    PubMed    


  28. CHAN LN
    Cardiovascular Risk Reduction with Icosapent Ethyl.
    N Engl J Med. 2019;380:1677.
    PubMed    


    March 2019
  29. FERENCE BA, Ray KK, Catapano AL, Ference TB, et al
    Mendelian Randomization Study of ACLY and Cardiovascular Disease.
    N Engl J Med. 2019;380:1033-1042.
    PubMed     Abstract available


  30. RAY KK, Bays HE, Catapano AL, Lalwani ND, et al
    Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
    N Engl J Med. 2019;380:1022-1032.
    PubMed     Abstract available


    January 2019
  31. KASTELEIN JJP, Stroes ESG
    FISHing for the Miracle of Eicosapentaenoic Acid.
    N Engl J Med. 2019;380:89-90.
    PubMed    


    November 2018
  32. BHATT DL, Steg PG, Miller M, Brinton EA, et al
    Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812792.
    PubMed     Abstract available


  33. SCHWARTZ GG, Steg PG, Szarek M, Bhatt DL, et al
    Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
    N Engl J Med. 2018 Nov 7. doi: 10.1056/NEJMoa1801174.
    PubMed     Abstract available


    August 2018
  34. RAWSHANI A, Rawshani A, Franzen S, Sattar N, et al
    Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2018;379:633-644.
    PubMed     Abstract available


    May 2018
  35. KOEHLER VF, Parhofer KG
    Xanthoma Striatum Palmare.
    N Engl J Med. 2018;378:e26.
    PubMed    


    November 2017
  36. CALABRO P, Gragnano F, Pirro M
    Cognitive Function in a Randomized Trial of Evolocumab.
    N Engl J Med. 2017;377:1996-7.
    PubMed    


  37. GIUGLIANO RP, Sabatine MS, Ott BR
    Cognitive Function in a Randomized Trial of Evolocumab.
    N Engl J Med. 2017;377:1997.
    PubMed    


    August 2017
  38. POONIA A, Giridhara P
    Xanthomas in Familial Hypercholesterolemia.
    N Engl J Med. 2017;377:e7.
    PubMed    


    July 2017
  39. GAUDET D, Gipe DA, Pordy R, Ahmad Z, et al
    ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia.
    N Engl J Med. 2017;377:296-297.
    PubMed    


    April 2017
  40. RIDKER PM, Tardif JC, Amarenco P, Duggan W, et al
    Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
    N Engl J Med. 2017;376:1517-1526.
    PubMed     Abstract available


  41. BEIGNEUX AP, Miyashita K, Ploug M, Blom DJ, et al
    Autoantibodies against GPIHBP1 as a Cause of Hypertriglyceridemia.
    N Engl J Med. 2017 Apr 5. doi: 10.1056/NEJMoa1611930.
    PubMed     Abstract available


    March 2017
  42. RAY KK, Landmesser U, Leiter LA, Kallend D, et al
    Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
    N Engl J Med. 2017 Mar 17. doi: 10.1056/NEJMoa1615758.
    PubMed     Abstract available


  43. RIDKER PM, Revkin J, Amarenco P, Brunell R, et al
    Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
    N Engl J Med. 2017 Mar 17. doi: 10.1056/NEJMoa1701488.
    PubMed     Abstract available


  44. SABATINE MS, Giugliano RP, Keech AC, Honarpour N, et al
    Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
    N Engl J Med. 2017 Mar 17. doi: 10.1056/NEJMoa1615664.
    PubMed     Abstract available


    February 2017
  45. KHERA AV, Kathiresan S
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:498-9.
    PubMed    


  46. MARTIN AC, Watts GF
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:498.
    PubMed    


  47. KULLO IJ, Safarova MS
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:498.
    PubMed    


  48. HINGORANI AD, Futema M, Humphries S
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:499.
    PubMed    



  49. Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2017;376:498-500.
    PubMed    


    January 2017
  50. SCHULMAN AR, Vaidya A, Tavakkoli A, Jajoo K, et al
    Making the Connection.
    N Engl J Med. 2017;376:e5.
    PubMed    


    October 2016
  51. MCCRINDLE BW, Gidding SS
    What Should Be the Screening Strategy for Familial Hypercholesterolemia?
    N Engl J Med. 2016;375:1685-1686.
    PubMed    


  52. WALD DS, Bestwick JP, Morris JK, Whyte K, et al
    Child-Parent Familial Hypercholesterolemia Screening in Primary Care.
    N Engl J Med. 2016;375:1628-1637.
    PubMed     Abstract available


    September 2016
  53. LAMPSON BL, Gray SW, Cibas ES, Levy BD, et al
    CLINICAL PROBLEM-SOLVING. Tip of the Tongue.
    N Engl J Med. 2016;375:880-6.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: